FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2329680963> ?p ?o ?g. }

• W2329680963 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCTreatment with aromatase inhibitors (AI's) is highly effective against breast cancer in ER positive postmenopausal women. However, some patients eventually become resistant to AIs. Tumor initiating cells (TIC's) represent a subpopulation of tumor cells, which show self-renewal capacity. We are focused towards discovering strategies to reduce the growth of breast cancer TICs, which may result in resistance. We have developed a xenograft model that mimics post-menopausal hormone responsive breast cancer. In this model, aromatase transfected human hormone sensitive MCF-7 cells (MCF-7Ca) are inoculated in ovariectomized athymic nude mice and allowed to grow in presence of Δ4A (aromatizable substrate of estrogen). Using this model, we have established that although AI letrozole provides a longer control over tumor growth, tumors eventually began to grow. In the current study, we investigated the effect of ATRA (All-trans Retinoic acid) (125μg/day, ip) and a histone deacetylase (HDAC) inhibitor entinostat (SNDX- 275) (50μg/day, po) with or without letrozole on letrozole resistant tumors in a xenograft model system. Ovariectomized athymic nude mice bearing xenografts of MCF-7Ca cells were treated with letrozole till they became resistant (15 weeks). At this time, the mice were grouped to receive ATRA, entinostat plus ATRA or the combination of ATRA plus entinostat plus letrozole till week 23. The mice treated with entinostat plus ATRA plus letrozole showed a significant decrease in tumor growth rate compared to mice treated with single agents or entinostat plus ATRA (p<0.0001, p=0.02). On week 20, two mice from each treatment group were euthanized and tumors were harvested. The tumors were digested enzymatically with collagenase and hyaluronidase and freed of debris using centrifugation and filtration. Mammosphere forming ability of TICs in the tumor tissue was measured by seeding 10,000 viable cells from each treated tumors under non-adherent conditions to access the self-renewal capacity. The combination of ATRA plus ENT plus letrozole significantly (p<0.01) reduced number of mammospheres formed compared to single agents alone. Quantitative PCR analysis of tumors cells showed a significant downregulation of the known TIC molecular markers, BCRP, ALDH, BMI-1 and Nanog compared to letrozole treated tumors. Similar results were also obtained when LTLT-Ca (long term letrozole treated MCF-7Ca) cells were treated with ATRA and entinostat in combination with letrozole and then seeded (5000 cells) in non-adherent conditions. Combination of ATRA plus entinostat plus letrozole significantly (p<0.0001) reduced mammosphere-forming ability of the LTLT-Ca cells. Overall, these studies indicate that the combination of ATRA, entinostat and letrozole is effective in reducing tumor recurrence in letrozole resistant tumors.Citation Format: Preeti Shah, Gauri J. Sabnis, Olga Goloubeva, Armina Kazi, Amanda Schech, Rabia Gilani, Yael Gau, Saranya Chumsri, Angela Brodie. Preclinical assessment of an HDAC inhibitor combined with a retinoid in AI resistant breast cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1311. doi:10.1158/1538-7445.AM2013-1311" @default.
• W2329680963 created "2016-06-24" @default.
• W2329680963 creator A5001999675 @default.
• W2329680963 creator A5012068082 @default.
• W2329680963 creator A5014065158 @default.
• W2329680963 creator A5018533808 @default.
• W2329680963 creator A5052187738 @default.
• W2329680963 creator A5058896231 @default.
• W2329680963 creator A5063329754 @default.
• W2329680963 creator A5068878390 @default.
• W2329680963 creator A5072945710 @default.
• W2329680963 date "2013-04-15" @default.
• W2329680963 modified "2023-09-27" @default.
• W2329680963 title "Abstract 1311: Preclinical assessment of an HDAC inhibitor combined with a retinoid in AI resistant breast cancer." @default.
• W2329680963 doi "https://doi.org/10.1158/1538-7445.am2013-1311" @default.
• W2329680963 hasPublicationYear "2013" @default.
• W2329680963 type Work @default.
• W2329680963 sameAs 2329680963 @default.
• W2329680963 citedByCount "0" @default.
• W2329680963 crossrefType "proceedings-article" @default.
• W2329680963 hasAuthorship W2329680963A5001999675 @default.
• W2329680963 hasAuthorship W2329680963A5012068082 @default.
• W2329680963 hasAuthorship W2329680963A5014065158 @default.
• W2329680963 hasAuthorship W2329680963A5018533808 @default.
• W2329680963 hasAuthorship W2329680963A5052187738 @default.
• W2329680963 hasAuthorship W2329680963A5058896231 @default.
• W2329680963 hasAuthorship W2329680963A5063329754 @default.
• W2329680963 hasAuthorship W2329680963A5068878390 @default.
• W2329680963 hasAuthorship W2329680963A5072945710 @default.
• W2329680963 hasConcept C104317684 @default.
• W2329680963 hasConcept C121608353 @default.
• W2329680963 hasConcept C126322002 @default.
• W2329680963 hasConcept C143998085 @default.
• W2329680963 hasConcept C2776166826 @default.
• W2329680963 hasConcept C2776202225 @default.
• W2329680963 hasConcept C2778305200 @default.
• W2329680963 hasConcept C2778504769 @default.
• W2329680963 hasConcept C2778812593 @default.
• W2329680963 hasConcept C2780110267 @default.
• W2329680963 hasConcept C502942594 @default.
• W2329680963 hasConcept C530470458 @default.
• W2329680963 hasConcept C55493867 @default.
• W2329680963 hasConcept C64927066 @default.
• W2329680963 hasConcept C71924100 @default.
• W2329680963 hasConcept C86803240 @default.
• W2329680963 hasConcept C98274493 @default.
• W2329680963 hasConceptScore W2329680963C104317684 @default.
• W2329680963 hasConceptScore W2329680963C121608353 @default.
• W2329680963 hasConceptScore W2329680963C126322002 @default.
• W2329680963 hasConceptScore W2329680963C143998085 @default.
• W2329680963 hasConceptScore W2329680963C2776166826 @default.
• W2329680963 hasConceptScore W2329680963C2776202225 @default.
• W2329680963 hasConceptScore W2329680963C2778305200 @default.
• W2329680963 hasConceptScore W2329680963C2778504769 @default.
• W2329680963 hasConceptScore W2329680963C2778812593 @default.
• W2329680963 hasConceptScore W2329680963C2780110267 @default.
• W2329680963 hasConceptScore W2329680963C502942594 @default.
• W2329680963 hasConceptScore W2329680963C530470458 @default.
• W2329680963 hasConceptScore W2329680963C55493867 @default.
• W2329680963 hasConceptScore W2329680963C64927066 @default.
• W2329680963 hasConceptScore W2329680963C71924100 @default.
• W2329680963 hasConceptScore W2329680963C86803240 @default.
• W2329680963 hasConceptScore W2329680963C98274493 @default.
• W2329680963 hasLocation W23296809631 @default.
• W2329680963 hasOpenAccess W2329680963 @default.
• W2329680963 hasPrimaryLocation W23296809631 @default.
• W2329680963 hasRelatedWork W1679717407 @default.
• W2329680963 hasRelatedWork W1931233949 @default.
• W2329680963 hasRelatedWork W1968113878 @default.
• W2329680963 hasRelatedWork W1990914272 @default.
• W2329680963 hasRelatedWork W2004774166 @default.
• W2329680963 hasRelatedWork W2076656264 @default.
• W2329680963 hasRelatedWork W2138599916 @default.
• W2329680963 hasRelatedWork W2147514757 @default.
• W2329680963 hasRelatedWork W2171335562 @default.
• W2329680963 hasRelatedWork W2313896852 @default.
• W2329680963 hasRelatedWork W2324291173 @default.
• W2329680963 hasRelatedWork W2325109592 @default.
• W2329680963 hasRelatedWork W2325840092 @default.
• W2329680963 hasRelatedWork W2326115840 @default.
• W2329680963 hasRelatedWork W2328982042 @default.
• W2329680963 hasRelatedWork W2331565235 @default.
• W2329680963 hasRelatedWork W2333657505 @default.
• W2329680963 hasRelatedWork W2334696060 @default.
• W2329680963 hasRelatedWork W2566462879 @default.
• W2329680963 hasRelatedWork W2912119489 @default.
• W2329680963 isParatext "false" @default.
• W2329680963 isRetracted "false" @default.
• W2329680963 magId "2329680963" @default.
• W2329680963 workType "article" @default.